Multiple system atrophy: A clinical and neuropathological perspective

Trends in Neurosciences

Volumn 34, Issue 11, 2011, Pages 581-590

  Ubhi, Kiren ^a   Low, Phillip ^c   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; LEVODOPA;

AMNESIA; BODY EQUILIBRIUM; CLINICAL TRIAL (TOPIC); DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; ERECTILE DYSFUNCTION; HUMAN; NERVE CELL; NERVE DEGENERATION; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; RIGIDITY; SHY DRAGER SYNDROME; TRANSGENIC ANIMAL;

ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MULTIPLE SYSTEM ATROPHY; OLIGODENDROGLIA;

EID: 82455205801     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2011.08.003     Document Type: Review

References (117)

1. Selkoe D. Amyloid β-protein deposition as a seminal pathogenic event in AD: an hypothesis. Neurobiol. Aging 1990, 11:299.
2. Vonsattel J.P., et al. Huntington's disease - neuropathology. Handb. Clin. Neurol. 2011, 100:83-100.
3. Kahle P.J. α-Synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115:87-95.
4. Graham J.G., Oppenheimer D.R. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 1969, 32:28-34.
5. Geser F., et al. The European Multiple System Atrophy-Study Group (EMSA-SG). J. Neural. Transm. 2005, 112:1677-1686.
6. Gilman S., et al. The North American Multiple System Atrophy Study Group. J. Neural. Transm. 2005, 112:1687-1694.
7. Stefanova N., et al. Multiple system atrophy: an update. Lancet Neurol. 2009, 8:1172-1178.
8. Schrag A., et al. Survival in multiple system atrophy. Mov. Disord. 2008, 23:294-296.
9. Burn D.J., Jaros E. Multiple system atrophy: cellular and molecular pathology. Mol. Pathol. 2001, 54:419-426.
10. Gilman S., et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin. Auton. Res. 1998, 8:359-362.
11. Kosaka K. Lewy bodies in cerebral cortex. Report of three cases. Acta Neuropathol. (Berl) 1978, 42:127-134.
12. Kosaka K. Diffuse Lewy body disease in Japan. J. Neurol. 1990, 237:197-204.
13. Kosaka K., et al. Diffuse type of Lewy body disease. Progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree - a new disease?. Clin. Neuropathol. 1984, 3:183-192.
14. Schrag A., et al. Measuring health-related quality of life in MSA: the MSA-QoL. Mov. Disord. 2007, 22:2332-2338.
15. Schrag A., et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov. Disord. 2010, 25:1077-1081.
16. Dujardin K., et al. Executive function differences in multiple system atrophy and Parkinson's disease. Parkinsonism Relat. Disord. 2003, 9:205-211.
17. Fetoni V., et al. Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy. J. Neurol. Neurosurg. Psychiatry 1999, 66:541-544.
18. Benrud-Larson L.M., et al. Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov. Disord. 2005, 20:951-957.
19. Yabe I., et al. MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA. J. Neurol. Sci. 2006, 249:115-121.
20. Pfeiffer R.F. Multiple system atrophy. Handb. Clin. Neurol. 2007, 84:305-326.
21. Mathias C.J. Multiple system atrophy and autonomic failure. J. Neural. Transm. Suppl. 2006, 70:343-347.
22. Kollensperger M., et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov. Disord. 2010, 25:2604-2612.
23. Gilman S., et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71:670-676.
24. Flabeau O., et al. Multiple system atrophy: current and future approaches to management. Ther. Adv. Neurol. Disord. 2010, 3:249-263.
25. Low P.A., Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol. 2008, 7:451-458.
26. Parati E.A., et al. Response to L-DOPA in multiple system atrophy. Clin. Neuropharmacol. 1993, 16:139-144.
27. Boesch S.M., et al. Dystonia in multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 2002, 72:300-303.
28. Christine C.W., Aminoff M.J. Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance. Am. J. Med. 2004, 117:412-419.
29. Wenning G.K., et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov. Disord. 2004, 19:1391-1402.
30. Papp M.I., et al. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci. 1989, 94:79-100.
31. Jellinger K.A., Lantos P.L. Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol. 2010, 119:657-667.
32. Kato S., Nakamura H. Cytoplasmic argyrophilic inclusions in neurons of pontine nuclei in patients with olivopontocerebellar atrophy: immunohistochemical and ultrastructural studies. Acta Neuropathol. 1990, 79:584-594.
33. Kato S., et al. Argyrophilic ubiquitinated cytoplasmic inclusions of Leu-7-positive glial cells in olivopontocerebellar atrophy (multiple system atrophy). Acta Neuropathol. 1991, 82:488-493.
34. Murayama S., et al. Immunocytochemical and ultrastructural studies of neuronal and oligodendroglial cytoplasmic inclusions in multiple system atrophy. 2. Oligodendroglial cytoplasmic inclusions. Acta Neuropathol. 1992, 84:32-38.
35. Arima K., et al. Immunocytochemical and ultrastructural studies of neuronal and oligodendroglial cytoplasmic inclusions in multiple system atrophy. 1. Neuronal cytoplasmic inclusions. Acta Neuropathol. 1992, 83:453-460.
36. Papp M.I., Lantos P.L. Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. J. Neurol. Sci. 1992, 107:172-182.
37. Iwai A., et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995, 14:467-475.
38. Maroteaux L., et al. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 1988, 8:2804-2815.
39. Weinreb P.H., et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996, 35:13709-13715.
40. Wakabayashi K., et al. α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 1998, 249:180-182.
41. Spillantini M.G., et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 1998, 251:205-208.
42. Arima K., et al. NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol. 1998, 96:439-444.
43. Tu P.H., et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol. 1998, 44:415-422.
44. Nakazato Y., et al. Oligodendroglial microtubular tangles in olivopontocerebellar atrophy. J. Neuropathol. Exp. Neurol. 1990, 49:521-530.
45. Goedert M. Parkinson's disease and other alpha-synucleinopathies. Clin. Chem. Lab. Med. 2001, 39:308-312.
46. Goedert M. α-Synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2001, 2:492-501.
47. Spillantini M.G., et al. α-Synuclein in Lewy bodies. Nature 1997, 388:839-840.
48. Tong J., et al. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain 2010, 133:172-188.
49. Klucken J., et al. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. Acta Neuropathol. 2006, 111:101-108.
50. Hashimoto M., Masliah E. α-Synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol. 1999, 9:707-720.
51. Masliah E., et al. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am. J. Pathol. 1996, 148:201-210.
52. Kahle P.J., et al. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 2002, 3:583-588.
53. Shults C.W., et al. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J. Neurosci. 2005, 25:10689-10699.
54. Yazawa I., et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005, 45:847-859.
55. Stemberger S., et al. Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. Exp. Neurol. 2010, 224:459-464.
56. Meco G., et al. Attentional functions in multiple system atrophy and Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1996, 60:393-398.
57. Robbins T.W., et al. Cognitive performance in multiple system atrophy. Brain 1992, 115:271-291.
58. Stefanova N., et al. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am. J. Pathol. 2005, 166:869-876.
59. Ubhi K., et al. Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. J. Neurosci. Res. 2009, 87:2728-2739.
60. Dufty B.M., et al. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 2007, 170:1725-1738.
61. Beyer K. α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 2006, 112:237-251.
62. Gorbatyuk O.S., et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:763-768.
63. Oueslati A., et al. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res. 2010, 183:115-145.
64. Jin H., et al. Analyses of copy number and mRNA expression level of the alpha-synuclein gene in multiple system atrophy. J. Med. Dent. Sci. 2008, 55:145-153.
65. Miller D.W., et al. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J. Neural. Transm. 2005, 112:1613-1624.
66. Ozawa T., et al. Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol. 2001, 102:188-190.
67. Kordower J.H., et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 2008, 14:504-506.
68. Lee S.J. Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. J. Mol. Neurosci. 2008, 34:17-22.
69. Lee S.J., et al. Cell-to-cell transmission of non-prion protein aggregates. Nat. Rev. Neurol. 2010, 6:702-706.
70. Lee H.J., et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 2010, 285:9262-9272.
71. Desplats P., et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:13010-13015.
72. Hansen C., et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 2011, 121:715-725.
73. Beyer K., Ariza A. Protein aggregation mechanisms in synucleinopathies: commonalities and differences. J. Neuropathol. Exp. Neurol. 2007, 66:965-974.
74. Halliday G.M., et al. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 2011, 122:187-204.
75. Ischiropoulos H. Oxidative modifications of alpha-synuclein. Ann. N.Y. Acad. Sci. 2003, 991:93-100.
76. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
77. Franco R., et al. Molecular mechanisms of pesticide-induced neurotoxicity: relevance to Parkinson's disease. Chem. Biol. Interact 2010, 188:289-300.
78. Xie W., et al. New insights into the role of mitochondrial dysfunction and protein aggregation in Parkinson's disease. Biochim. Biophys Acta 2011, 1802:935-941.
79. McCoy M.K., Cookson M.R. DJ-1 regulation of mitochondrial function and autophagy through oxidative stress. Autophagy 2011, 7:531-532.
80. Akundi R.S., et al. Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PLoS ONE 2011, 6:e16038.
81. Hanna P.A., et al. Multiple system atrophy: the putative causative role of environmental toxins. Arch. Neurol. 1999, 56:90-94.
82. Soma H., et al. Associations between multiple system atrophy and polymorphisms of SLC1A4, SQSTM1, and EIF4EBP1 genes. Mov. Disord. 2008, 23:1161-1167.
83. Ubhi K., et al. α-Synuclein deficient mice are resistant to toxin-induced multiple system atrophy. Neuroreport 2010, 21:457-462.
84. Ubhi K., et al. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J. Neurosci. 2010, 30:6236-6246.
85. Ischiropoulos H., Beckman J.S. Oxidative stress and nitration in neurodegeneration: cause, effect, or association?. J. Clin. Invest. 2003, 111:163-169.
86. Norris E.H., et al. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 2005, 280:21212-21219.
87. Norris E.H., et al. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J. Biol. Chem. 2003, 278:27230-27240.
88. Ono K., Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J. Neurochem. 2006, 97:105-115.
89. Ubhi K., et al. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 2008, 19:1271-1276.
90. Song Y.J., et al. p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am. J. Pathol. 2007, 171:1291-1303.
91. Lindersson E., et al. p25alpha stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J. Biol. Chem. 2005, 280:5703-5715.
92. Hasegawa T., et al. Role of TPPP/p25 on alpha-synuclein-mediated oligodendroglial degeneration and the protective effect of SIRT2 inhibition in a cellular model of multiple system atrophy. Neurochem. Int. 2010, 57:857-866.
93. Du Y., Dreyfus C.F. Oligodendrocytes as providers of growth factors. J. Neurosci. Res. 2002, 68:647-654.
94. Wilkins A., et al. Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. J. Neurosci. 2003, 23:4967-4974.
95. Dai X., et al. The trophic role of oligodendrocytes in the basal forebrain. J. Neurosci. 2003, 23:5846-5853.
96. Wilkins A., et al. A role for oligodendrocyte-derived IGF-1 in trophic support of cortical neurons. Glia 2001, 36:48-57.
97. Nutt J.G., et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60:69-73.
98. Hong M., et al. GDNF therapy for Parkinson's disease. Expert Rev. Neurother. 2008, 8:1125-1139.
99. Kells A.P., et al. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J. Neurosci. 2010, 30:9567-9577.
100. Blandini F., et al. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp. Neurol. 2004, 187:455-459.
101. Zhu W., et al. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J. Neurochem. 2008, 105:1970-1978.
102. Olanow C.W., et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov. Disord. 2008, 23:2194-2201.
103. Sampaio C., Ferreira J.J. Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression. Nat. Rev. Neurol. 2010, 6:126-128.
104. Weinreb O., et al. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann. N.Y. Acad. Sci. 2007, 1122:155-168.
105. Stefanova N., et al. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp. Neurol. 2008, 210:421-427.
106. Li J., et al. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem. Biol. 2004, 11:1513-1521.
107. Park H.J., et al. Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy-parkinsonism. Cell Transplant. 2011, 20:827-835.
108. Kollensperger M., et al. Striatal transplantation in a rodent model of multiple system atrophy: effects on L-Dopa response. J. Neurosci. Res. 2009, 87:1679-1685.
109. Stefanova N., et al. Striatal transplantation for multiple system atrophy - are grafts affected by alpha-synucleinopathy?. Exp. Neurol. 2009, 219:368-371.
110. Li J.Y., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
111. Mendez I., et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 2008, 14:507-509.
112. Brundin P., et al. Research in motion: the enigma of Parkinson's disease pathology spread. Nat. Rev. Neurosci. 2008, 9:741-745.
113. Masliah E., et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 2011, 6:e19338.
114. Hirohata M., et al. Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro alpha-synuclein fibril formation. Neurosci. Lett. 2011, 491:48-52.
115. Shi M., et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011, 69:570-580.
116. Yoshida M. Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology 2007, 27:484-493.
117. Kollensperger M., Wenning G.K. Assessing disease progression with MRI in atypical parkinsonian disorders. Mov. Disord. 2009, 24(Suppl. 2):S699-S702.